American Association for Cancer Research
mcr-23-0386_figure_s8_suppsf8.pdf (400.57 kB)

Figure S8 from Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma

Download (400.57 kB)
journal contribution
posted on 2024-01-02, 08:20 authored by Sho Tabata, Shigeki Umemura, Miyu Narita, Hibiki Udagawa, Takamasa Ishikawa, Masahiro Tsuboi, Koichi Goto, Genichiro Ishii, Katsuya Tsuchihara, Atsushi Ochiai, Susumu S. Kobayashi, Tomoyoshi Soga, Hideki Makinoshima

Metabolic profile in SCLC patient's plasma


Japan Society for the Promotion of Science (JSPS)



Small cell lung cancer (SCLC) has a poor prognosis, emphasizing the necessity for developing new therapies. The de novo synthesis pathway of purine nucleotides, which is involved in the malignant growth of SCLC, has emerged as a novel therapeutic target. Purine nucleotides are supplied by two pathways: de novo and salvage. However, the role of the salvage pathway in SCLC and the differences in utilization and crosstalk between the two pathways remain largely unclear. Here, we found that deletion of the HPRT1 gene, which codes for the rate-limiting enzyme of the purine salvage pathway, significantly suppressed tumor growth in vivo in several SCLC cells. We also demonstrated that HPRT1 expression confers resistance to lemetrexol (LMX), an inhibitor of the purine de novo pathway. Interestingly, HPRT1-knockout had less effect on SCLC SBC-5 cells, which are more sensitive to LMX than other SCLC cell lines, suggesting that a preference for either the purine de novo or salvage pathway occurs in SCLC. Furthermore, metabolome analysis of HPRT1-knockout cells revealed increased intermediates in the pentose phosphate pathway and elevated metabolic flux in the purine de novo pathway, indicating compensated metabolism between the de novo and salvage pathways in purine nucleotide biosynthesis. These results suggest that HPRT1 has therapeutic implications in SCLC and provide fundamental insights into the regulation of purine nucleotide biosynthesis. SCLC tumors preferentially utilize either the de novo or salvage pathway in purine nucleotide biosynthesis, and HPRT1 has therapeutic implications in SCLC.

Usage metrics

    Molecular Cancer Research



    Ref. manager